Cardiometabolic Effects on Health with GLP-1 Receptor Therapy

GLP-1 receptor therapy for cardiometabolic conditions is reshaping the treatment landscape for metabolic health. Find out why.

Abstract

In this educational post, I guide you through a modern, risk-reduction paradigm for managing type 2 diabetes, cardiovascular disease, and chronic kidney disease. I explain how regulatory-driven cardiovascular outcome trials revealed unexpected, protective benefits of two medication classes — SGLT2 inhibitors and GLP-1 receptor agonists — reshaping guidelines from the ADA, AHA, ACC, and KDIGO. I present the physiological underpinnings behind these therapies, including natriuresis, intraglomerular pressure modulation, myocardial fuel efficiency, and incretin biology, and show how these mechanisms translate into reduced hospitalization for heart failure, decreased major adverse cardiovascular events (MACE), and slowed chronic kidney disease progression. I also detail how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas — under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933) — integrates my chiropractic care, functional medicine, rehabilitation, and personal injury services with advanced medical oversight to create individualized care plans. Through real-world case narratives, practical protocols, and clinical insights from my work at Push-as-Rx and my professional activity on LinkedIn, I demonstrate how combining evidence-based pharmacology with integrative chiropractic strategies delivers holistic outcomes that protect the heart and kidneys while optimizing metabolic health (American Diabetes Association Professional Practice Committee, 2024; Marso et al., 2016; Zinman et al., 2015; McMurray et al., 2019).

Our Multidisciplinary Team: Medical Direction Meets Chiropractic Integration

I practice within a multidisciplinary, integrative framework at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. Our model is purposefully designed to support complex cardiometabolic needs alongside musculoskeletal and injury recovery.

• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), with over 40 years of experience, provides comprehensive medical oversight, ensures safety, and aligns our protocols with conventional standards of care.
• Chiropractic and Functional Medicine Integration: I serve as Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, integrating chiropractic biomechanics, neuromuscular rehabilitation, and functional medicine to address root causes affecting cardiometabolic health.
• Unified Service Delivery:

• • Chiropractic Care: Pain reduction, joint mobility restoration, autonomic balance, posture optimization.
  • Internal Medicine Oversight: Diagnosis, risk stratification, medication selection, and adherence to cardiometabolic guidelines.
  • Functional Medicine: Nutrition, lifestyle strategies, stress modulation, and gut-brain axis optimization.
  • Rehabilitation and Personal Injury Care: Safe return to activity, kinetic chain reinforcement, and tailored corrective exercise.

This setup — an MD providing medical direction alongside a chiropractor — is a common and effective approach in integrative and injury care clinics, and it allows us to deliver comprehensive, patient-centered care that is both evidence-based and holistic.

The Paradigm Shift: Beyond Blood Sugar to Comprehensive Risk Reduction

For decades, diabetes care focused primarily on glucose lowering. Today, a more effective paradigm drives clinical decisions: global risk reduction across the heart, kidneys, and vasculature. The leading societies — the American Diabetes Association (ADA), American College of Cardiology (ACC), American Heart Association (AHA), and KDIGO — now recommend prioritizing therapies that reduce cardiovascular and renal events, often independent of glycemic changes (American Diabetes Association Professional Practice Committee, 2024).

• Why the shift occurred:

• • People with diabetes experience disproportionately high risks of ASCVD, heart failure, and chronic kidney disease.
  • Mortality after myocardial infarction or stroke is significantly higher in diabetes, even with finely controlled glucose.
  • Longitudinal data demonstrate that blood pressure, lipids, weight, and smoking drive long-term outcomes at least as much as A1c.

• Core pillars in modern risk reduction:

• • Blood pressure control
  • LDL cholesterol reduction
  • Weight management
  • Physical activity
  • Smoking cessation
  • Cardioprotective and renoprotective medications with outcome-based evidence

This unified approach marks a new era: we treat metabolic disease as a cardiometabolic syndrome, optimizing organ protection while controlling glucose.

How CVOTs Changed Everything: From Safety Mandates to Discoveries

In 2008, the FDA required Cardiovascular Outcome Trials (CVOTs) for all new diabetes drugs to ensure they did not increase MACE (nonfatal MI, nonfatal stroke, cardiovascular death). These trials were long, robust, and powered for outcomes — and they delivered surprises.

• Key result: Several new medications were not merely safe — they conferred significant cardiovascular and renal
• Clinical impact: Guidelines elevated SGLT2 inhibitors and GLP-1 receptor agonists for patients with established ASCVD, heart failure, or chronic kidney disease, often irrespective of baseline A1c (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019; Marso et al., 2016; Gerstein et al., 2019).

This mandate for rigorous outcomes catalyzed a shift from glucose-centric thinking to risk-based prescribing.

SGLT2 Inhibitors: Guardians of the Heart and Kidneys

SGLT2 inhibitors reduce glucose reabsorption in the proximal renal tubule, leading to glycosuria and natriuresis. Their benefits extend well beyond glucose lowering and arise from convergent hemodynamic, renal, metabolic, and anti-inflammatory mechanisms.

Landmark SGLT2 CVOTs and Renal Trials

• EMPA-REG OUTCOME (empagliflozin): Significant reductions in cardiovascular death, MACE, and hospitalization for heart failure (Zinman et al., 2015).
• CANVAS Program (canagliflozin): Reduced MACE and heart failure hospitalizations (Neal et al., 2017).
• DECLARE-TIMI 58 (dapagliflozin): Robust reduction in heart failure hospitalizations; broader population, including primary prevention (Wiviott et al., 2019).
• VERTIS CV (ertugliflozin): Meaningful reduction in heart failure hospitalizations.
• DAPA-HF, EMPEROR-Reduced: 25–26% relative risk reduction in CV death or HF hospitalization in HFrEF — effective even without diabetes (McMurray et al., 2019).
• EMPEROR-Preserved: First meaningful outcome benefit in HFpEF (Anker et al., 2021).
• DAPA-CKD, EMPA-KIDNEY: Trials stopped early for efficacy; 39–47% reductions in CKD progression (consistent renoprotection).

Why SGLT2s Protect the Heart and Kidneys

• Hemodynamic modulation: Mild diuresis and natriuresis lower preload and afterload, reduce systolic BP (~5 mmHg), and unload the heart.
• Intraglomerular pressure reduction: Tubuloglomerular feedback reduces hyperfiltration, protecting glomeruli and slowing nephropathy
• Myocardial fuel shift: Favoring ketone utilization enhances myocardial efficiency, mitigating energetic stress in heart failure.
• Anti-inflammatory and antifibrotic effects: Lower oxidative stress and reduced tissue fibrosis support structural integrity of the myocardium and renal parenchyma.
• Weight and visceral adiposity: Modest weight loss (typically 5–7 pounds) improves insulin sensitivity and hemodynamics.

These multidimensional mechanisms make SGLT2 inhibitors a foundational therapy for heart failure and CKD, with or without diabetes.

GLP-1 Receptor Agonists: The Incretin Advantage for Cardio-Metabolic Protection

GLP-1 receptor agonists harness the incretin effect — the amplified insulin response to oral nutrient intake mediated by gut-derived hormones. In type 2 diabetes, the incretin system is blunted. GLP-1 agonists restore this physiology using potent, long-acting analogs.

Incretin Biology and System Effects

• Glucose-dependent insulin secretion: Enhances beta-cell insulin release only when glucose is elevated, thereby reducing the risk of hypoglycemia.
• Glucagon suppression: Lowers hepatic glucose output, smoothing fasting and postprandial profiles.
• Slowed gastric emptying: Dampens post-meal spikes and augments satiety, reducing caloric intake.
• Central appetite regulation: Hypothalamic signaling decreases hunger and cravings, supporting sustained weight loss (Nauck & Meier, 2018; Collins & Costello, 2023).

Cardiovascular Outcome Evidence

• LEADER (liraglutide): Significant reduction in MACE for high-risk patients (Marso et al., 2016).
• SUSTAIN-6 and PIONEER 6 (semaglutide): Consistent MACE reduction with both injectable and oral semaglutide (Marso et al., 2016; Husain et al., 2019).
• REWIND (dulaglutide): Demonstrated efficacy in patients with and without established ASCVD — primary and secondary prevention benefits (Gerstein et al., 2019).
• Renal signals: Trials and meta-analyses suggest improvements in albuminuria and renal outcomes; the semaglutide FLOW kidney trial reported early stopping for benefit.

Why GLP-1s Protect the Heart and Kidneys

• Anti-inflammatory actions: Plaque stabilization through attenuation of vascular inflammation.
• Endothelial benefits: Improved nitric oxide bioavailability and vascular relaxation.
• Blood pressure and lipid improvements: Modest reductions in BP and triglycerides contribute to reduced atherogenic burden.
• Cardiac myocyte support: Enhanced glucose uptake and cell survival pathways support LV function.
• Renal perfusion and metabolic relief: Downstream benefits from weight loss and improved hemodynamics reduce nephron workload.

Collectively, GLP-1 agonists offer powerful A1c reduction, substantial weight loss, and cardiovascular risk reduction, complementing the hemodynamic strengths of SGLT2 inhibitors.

Clinical Scenarios: Translating Evidence into Care

Case Study: Loretta — ASCVD and CKD Protection with SGLT2 Integration

Loretta is a 72-year-old with 15 years of type 2 diabetes, prior MI with stents (CAD), A1c 8.1%, and eGFR 55. She uses metformin and sitagliptin.

• Rationale for SGLT2 inhibitor:

• • Cardiovascular protection: Established ASCVD makes SGLT2 a first-line choice to lower future events and heart failure
  • Renal protection: eGFR decline and albuminuria risk require reducing intraglomerular pressure and preserving nephron function.
  • Glycemic gain: Typical A1c reduction up to ~1% aligns with her target.

• Practical steps:

• • Under Dr. Cardenas’s medical oversight, I recommend initiating an SGLT2 inhibitor, potentially combined with metformin to streamline adherence.
  • Hydration counseling to mitigate diuresis-related symptoms.
  • Hygiene guidance to reduce risk of genital mycotic infections.

• Chiropractic and functional integration:

• • Mobility and neuropathy support: Through adjustments, soft tissue work, and neuro-rehab, we reduce pain and improve gait and balance — enabling safe activity.
  • Nutrition: Anti-inflammatory, low-glycemic protocols emphasize fiber, lean protein, and healthy fats to complement pharmacology.
  • Quality of life: Reduced pain improves adherence to exercise and medications, reinforcing cardiometabolic improvements.

Case Study: Tony — Over-Basalization and GLP-1 Optimization

Tony is a 62-year-old male with 11 years of diabetes, A1c 8.2%, hypertension, dyslipidemia, proteinuria, and obesity (BMI 32.5). He uses degludec 65 units/day, metformin, an SGLT2 inhibitor, a statin, and an ARB. Fasting glucose ranges from 110–150 mg/dL; postprandial ranges from 160–200 mg/dL.

• Recognizing over-basalization:

• • Basal insulin dose exceeds 5 units/kg/day, with fasting control but persistent postprandial hyperglycemia and large bedtime-to-morning drops.
  • Adding prandial insulin increases the risk of hypoglycemia and further weight gain (Umar & Khan, 2022).

• GLP-1 as the next step:

• • ADA 2024 guidelines recommend GLP-1 RAs for high ASCVD risk: age >55 plus obesity, hypertension, dyslipidemia, albuminuria (American Diabetes Association Professional Practice Committee, 2024).
  • Semaglutide, liraglutide, or dulaglutide are preferred for proven MACE reduction; titrate slowly to minimize GI effects.
  • Synergy with SGLT2 inhibitor provides additive mechanisms: hemodynamic relief plus incretin-driven metabolic improvements.

• Chiropractic and rehab support:

• • Joint unloading and kinetic chain optimization: As weight drops, biomechanics shift; adjustments and corrective exercise prevent overuse injuries and enhance movement economy.
  • Neuropathy-focused modalities: Drawing from Push-as-Rx clinical pathways, we use targeted therapies to improve peripheral nerve function and microcirculation, aiding symptom relief and gait stability (Push-as-Rx; LinkedIn).
  • Satiety-centric nutrition: Prioritize lean protein and fiber to preserve muscle, improve satiety, and reduce GI intolerance with GLP-1 therapy.

Physiological Foundations: Why These Strategies Work

Understanding physiology clarifies why SGLT2 and GLP-1 therapies pair so well with integrative care.

• SGLT2 hemodynamics and nephron physiology:

• • By promoting natriuresis, SGLT2 inhibitors reduce plasma volume and BP, easing myocardial stress.
  • Afferent arteriolar signaling increases distal sodium delivery, restoring tubuloglomerular feedback and lowering intraglomerular pressure, which slows CKD progression.

• Myocardial energetics:

• • The heart’s efficiency improves when ketones supplement the fuel supply, especially in heart failure. SGLT2-driven shifts reduce oxygen demand per ATP generated.

• Incretin axis and gut-brain signaling:

• • GLP-1 agonists re-engage gut-derived insulinotropic signals and central satiety circuits, addressing postprandial hyperglycemia and caloric excess — two dominant drivers of cardiometabolic risk.

• Autonomic nervous system balance:

• • Chronic stress and sympathetic overactivity elevate cortisol and catecholamines, worsening insulin resistance and BP. Chiropractic care can help rebalance sympathetic-parasympathetic tone, supporting better glycemic and hemodynamic profiles.

• Musculoskeletal capacity and metabolic health:

• • Resistance training — embedded within rehab — maintains lean mass during weight loss, preserves RMR, and improves insulin-mediated glucose uptake. Joint alignment and soft tissue health increase exercise tolerance, enabling patients to meet activity prescriptions safely.

Safety, Side Effects, and Practical Considerations

We proactively manage safety to protect outcomes and patient comfort.

• SGLT2 inhibitors:

• • Watch for genital mycotic infections; emphasize hygiene.
  • Monitor for volume depletion; counsel hydration and BP checks.
  • Rare risks (euglycemic ketoacidosis) are mitigated by education and appropriate sick-day rules.

• GLP-1 receptor agonists:

• • GI effects (nausea, vomiting, constipation): Start low, titrate slowly; encourage smaller meals, avoid high-fat foods; consider ginger and hydration (Collins & Costello, 2023).
  • Gallbladder considerations: Rapid weight loss increases the risk of gallstones; monitor for biliary symptoms.
  • Pancreatitis: Large-scale analyses indicate no statistically significant increase; maintain vigilance and individual risk assessments.
  • Hydration to prevent AKI: Especially important if nausea reduces intake.
  • Peri-anesthesia management: Hold weekly GLP-1 doses 1–2 weeks before procedures to mitigate aspiration risk.
  • Contraindications: Personal/family history of medullary thyroid carcinoma (MTC) or MEN2 due to black box warnings.

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

How Integrative Chiropractic Care Fits into Cardiometabolic Treatment

In our clinic, chiropractic care is not an add-on; it is a core pillar that increases the real-world effectiveness of medical therapy.

• Pain reduction and mobility: By normalizing joint mechanics, reducing spinal and peripheral nociceptive input, and improving muscle recruitment, we enable consistent physical activity — a cornerstone of cardiometabolic improvement.
• Autonomic regulation: Spinal and soft tissue techniques can modulate autonomic tone, helping reduce physiological stress that drives insulin resistance and hypertension.
• Posture, gait, and function during weight loss: As GLP-1 therapies reshape body composition, biomechanics change. We guide patients through this transition to prevent new pain patterns and support sustainable activity.
• Neuropathy support: Through targeted protocols and modalities documented in my clinical work at Push-as-Rx and shared across my professional platforms, we address peripheral nerve symptoms to restore function and independence (Push-as-Rx; LinkedIn).
• Behavioral momentum: When pain decreases and energy increases, patients adhere better to medications, nutrition plans, and exercise — the synergy that converts evidence into outcomes.

Practical Care Pathway: Bringing It All Together

• Risk stratification under medical oversight (Dr. Cardenas):

• • ASCVD, heart failure phenotype (HFrEF vs. HFpEF), CKD staging, albuminuria status.
  • Selection and titration of SGLT2 inhibitors and GLP-1 agonists per guidelines and insurance navigation.

• Chiropractic and rehab integration (Dr. Jimenez):

• • Movement assessment, spinal and extremity adjustments, soft tissue therapies.
  • Progressive exercise plans emphasizing resistance training and functional capacity.
  • Neuropathy-oriented modalities, balance training, and fall prevention in older adults.

• Functional medicine and nutrition:

• • Anti-inflammatory, low-glycemic nutrition emphasizing protein for satiety and muscle preservation, fiber for glycemic control, and healthy fats for cardiometabolic stability.
  • Stress management strategies to reduce sympathetic load.
  • Sleep optimization to improve insulin sensitivity and recovery.

• Education and monitoring:

• • Clear discussions about side effects, hydration, sick-day rules, and peri-procedural medication holds.
  • Device-enabled glucose monitoring trends to identify over-basalization and target postprandial control with GLP-1 therapy.
  • Regular follow-up for kidney function, lipids, BP, weight trajectory, and functional metrics.

This integrated pipeline transforms cutting-edge research into personalized care, aligning medical direction with chiropractic and rehabilitation to protect the heart and kidneys while optimizing metabolic outcomes.

Conclusion: Evidence-Based Synergy for Whole-Person Health

SGLT2 inhibitors and GLP-1 receptor agonists ushered in a new era of cardiometabolic medicine, proving that diabetes therapies can prevent heart failure hospitalizations, reduce MACE, and slow CKD — often beyond their effects on glucose. When these agents are delivered within a multidisciplinary framework — with internal medicine oversight from Dr. Cardenas and integrative chiropractic care from me — patients benefit from a cohesive, whole-person strategy. We reduce pain, enhance function, modulate autonomic tone, and build the capacity for sustained lifestyle change — the practical ingredients of long-term risk reduction.

Our mission is clear: unify advanced, evidence-based pharmacology with chiropractic and functional medicine to help patients live longer, healthier, and more active lives.

References

• American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chordà, J., Chuquiure-Valenzuela, E., … Zannad, F. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Collins, L., & Costello, R. A. (2023). Glucagon-like peptide-1 receptor agonists. In StatPearls. StatPearls Publishing.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., … REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130.
• Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Hovingh, G. K., … PIONEER 6 Investigators. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841–851.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., … LEADER Steering Committee. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., … Hansen, T. F. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., … Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl 1), 5–21.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657.
• Umar, Z., & Khan, A. (2022). Insulin over-basalization: A clinical challenge in type 2 diabetes. Journal of the Pakistan Medical Association, 72(4), 803–806.
• Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., … Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347–357.
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., … Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.

SEO Tags: type 2 diabetes, cardiovascular disease, chronic kidney disease, SGLT2 inhibitors, GLP-1 receptor agonists, heart failure, integrative medicine, chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, ASCVD, risk reduction, nephropathy, empagliflozin, dapagliflozin, over-basalization, semaglutide, liraglutide, dulaglutide, REWIND, LEADER, SUSTAIN, EMPEROR-Preserved, DAPA-HF, EMPA-REG OUTCOME, ADA guidelines, KDIGO, ACC, AHA, Push-as-Rx, Mission Plaza Injury Medical Clinic